An Introduction to BIMO Listings [Video]

BIMO listings provide visibility into FDA Bioresearch Monitoring inspection outcomes across clinical investigators, sites, institutional review boards, sponsors, and data-related activities. This video explains how BIMO oversight connects submitted data back to the underlying clinical record, and how sponsors can use inspection findings to focus internal review and strengthen inspection readiness.

WHAT THIS VIDEO COVERS
• What BIMO is and how it relates to participant protection and data reliability
• What BIMO listings can reveal about recurring inspection findings
• Why BIMO oversight extends beyond final submission datasets
• How site-level issues can become wider sponsor oversight concerns
• The role of the BIMO Data Reviewer’s Guide in documenting submitted data
• How mock inspections, audit trails, and cross-functional review support readiness

BIMO readiness is easier to manage when documentation, data review, and oversight are built into study conduct rather than left until submission. Clear records, retrievable documentation, and explainable data handling can help teams understand where gaps exist before they become inspection issues.

Quanticate’s statistical programming team ensures BIMO compliance by delivering audit-ready datasets tailored to regulatory expectations. Our experts specialise in data validation, traceability, and documentation support, helping sponsors maintain data integrity. With automated workflows and robust programming solutions, we streamline FDA inspections and safeguard compliance. Request a consultation below to see how we can support your clinical research success.